Moreover, studies are in progress to assess the therapeutic potential of other anti-T2DM molecules, such as DPP-4 inhibitors (Kosaraju et al., 2017) and APN (Sekiyama et al., 2014; Waragai et al., 2018). Here, ANPEP is linked to type 2 diabetes mellitus.